Blood Purif. 2022 Nov 01. 1-9
INTRODUCTION: Among end-stage kidney disease (ESKD) patients on dialysis with autosomal dominant polycystic kidney disease (ADPKD), relatively little is known about the epidemiology and risk factors for 30-day readmissions in the USA. Therefore, we evaluated the 30-day unplanned readmission rates and predictors and inpatient care costs among ESKD patients with and without ADPKD using a nationally representative, all-payer database.
METHODS: We utilized the Nationwide Readmissions Database from 2013 to 2018 to identify patients admitted for ESKD on dialysis with and without ADPKD using ICD-9 and ICD-10 codes. The primary outcome was a 30-day, unplanned readmission rate. Secondary outcomes were readmission reasons and timing, mortality, cost of hospitalization and rehospitalization, and adjusted predictors of readmissions. We used χ2 tests, t tests, and Wilcoxon rank-sum tests for descriptive analyses and survey logistic regression to calculate adjusted odds ratios and 95% confidence intervals for associations with readmissions adjusting for confounders.
RESULTS: From 2013 to 2018, in a cohort of 1,404,144 hospitalizations with ESKD on dialysis as the primary and secondary diagnosis on index admission, there were 8,213 (0.58%) patients with ADPKD and 1,395,932 patients without ADPKD. Those who had ADPKD during index admissions had fewer 30 days readmissions (18.8 vs. 23.8%, p < 0.0001). The cost of hospitalizations and readmissions in ESKD on-dialysis patients with ADPKD was higher than non-ADPKD patients. Compared to ESKD patients without ADPKD who were readmitted, readmitted ADPKD patients were more likely to be younger with a lower Elixhauser Comorbidity Index (ECI) score; have received kidney transplant, lower source of income, elective index admissions, private insurance; and be discharged routinely, admitted in hospitals with larger bed size, in teaching hospitals, and less likely to get admitted through the emergency department. Younger age (<75 years), higher ECI score, longer length of stay, Medicare and Medicaid insurance, self-pay, discharge to a short-term hospital, specialized care, home health care, and against medical advice were associated with significantly increased odds of readmission. ADPKD patients were 31% less likely to get readmitted and 43% less likely to die during readmissions.
DISCUSSION/CONCLUSION: Nationwide, ESKD on-dialysis patients with ADPKD were less likely to have 30-day readmission than patients without ADPKD. Inpatient mortality during readmissions in patients admitted with ESKD on dialysis was lower with ADPKD as compared to those without ADPKD at the cost of higher health care expenses.
Keywords: Autosomal dominant polycystic kidney disease; End-stage kidney disease on dialysis; Epidemiology; Nationwide Readmissions Database; Readmission rates